Arcutis Biotherapeutics

Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its pipeline consists of topical treatments for plaque psoriasis, atopic dermatitis, hand eczema, vitiligo, scalp psoriasis, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne in June 2016 and is headquartered in Westlake Village, CA.

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Earnings data Q4 2025

Earnings data Q1 2026

Arcutis Biotherapeutics reports strong Q1 performance and growth opportunities

Arcutis Biotherapeutics showcased strong performance in Q1 2023, driven by ZORYVE's growth and expanding commercial coverage.
Despite challenges with gross-to-net dynamics and operational issues, the company remains confident in demand growth and product feedback.
Strategic initiatives focusing on market penetration, education, and partnerships position Arcutis well for future growth and product success.
Expansion into Canada, pricing strategy alignment, and disease awareness efforts offer promising opportunities for market expansion and acceptance.

Arcutis Biotherapeutics excels in Q2 with ZORYVE's growth and market expansion

Arcutis Biotherapeutics delivered a strong Q2 performance driven by ZORYVE's successful launch and coverage expansion, positioning the company for continued growth in Q3 and Q4.
Despite facing challenges in physician adoption and managing expenses, Arcutis benefits from key strengths like broad market access, positive physician feedback, and a robust patent estate.
With opportunities to capitalize on key payer agreements, expand into new indications, and drive market differentiation, Arcutis is poised for strategic growth and market expansion in the dermatology sector.

Arcutis Biotherapeutics excels in Q3, eyes market expansion opportunities

Arcutis Biotherapeutics showcased strong financial performance and key achievements in Q3 2023.
The successful ZORYVE launch and positive Phase III data highlight growth potential.
Strategic partnerships and market expansion plans position the company for future success.
Efforts to drive ZORYVE utilization and navigate market challenges are key focus areas.

Arcutis Biotherapeutics excels in Q4, poised for market expansion

Arcutis Biotherapeutics delivered strong financial performance and market acceptance in Q4 2023.
The company's focus on expanding its product portfolio and market reach bodes well for future growth.
Challenges in coverage negotiations and patient engagement require strategic solutions for sustained success.
Overall, Arcutis is well-positioned to capitalize on market opportunities and drive continued growth.

Arcutis Biotherapeutics reports strong Q1 performance and eyes market expansion

Arcutis Biotherapeutics anticipates sustained growth in 2024 and beyond, aiming to positively impact patients with chronic dermatologic diseases.
The company's focus on partnerships, market access optimization, and product expansion positions them well for future success in the dermatology market.
Despite challenges such as regulatory milestones and partnership negotiations, Arcutis remains confident in their ability to navigate these hurdles and drive continued growth.

Arcutis Biotherapeutics excels in Q2 2024, poised for growth

Arcutis Biotherapeutics delivered a strong performance in Q2 2024, driven by the success of ZORYVE products and strategic financial management.
While facing challenges in market expansion and operational efficiency, the company's focus on growth opportunities and profitability strategies bode well for future success.
Overall, Arcutis Biotherapeutics remains well-positioned to capitalize on market opportunities, expand product reach, and drive sustained revenue growth.

Arcutis Biotherapeutics excels in Q3, eyes growth through partnerships

Arcutis Biotherapeutics demonstrated strong sales growth, improved market access, and product label expansions in Q3 2024, positioning the company for future success.
While challenges like achieving breakeven and optimizing partnerships exist, opportunities from upcoming approvals and market trends present avenues for sustained growth.
Overall, Arcutis Biotherapeutics' strategic initiatives and performance in Q3 underscore its potential for long-term success and market leadership in dermatology.

Arcutis Biotherapeutics excels in 2024, eyes growth and market dominance

Arcutis Biotherapeutics delivered strong financial performance in 2024, driven by the success of ZORYVE and strategic market positioning. While facing challenges in achieving break-even and driving market adoption, the company is well-positioned for continued growth and market expansion. By leveraging growth opportunities, focusing on physician education, and navigating regulatory milestones, Arcutis aims to solidify its position in the dermatology market.

Arcutis Biotherapeutics reports strong Q1 performance and eyes FDA milestones

Arcutis Biotherapeutics delivered a strong Q1 2025 performance with notable revenue growth and product milestones. While facing challenges in quarterly revenue decline and market penetration, the company's strategic strengths and opportunities position it for future success. Management's focus on innovation, IP protection, and market expansion underscores a proactive approach to driving growth. Addressing analyst inquiries and capitalizing on upcoming FDA approvals can further enhance Arcutis' market position and revenue potential.

Arcutis Biotherapeutics reports robust Q2 results and eyes strategic growth

Arcutis Biotherapeutics delivered strong financial performance in Q2 2025, driven by revenue growth and operational improvements. While facing challenges such as R&D setbacks and competitive dynamics, the company's strategic strengths and growth opportunities position it well for the future. By focusing on expanding market share, leveraging expertise in dermatology, and pursuing disciplined growth strategies, Arcutis aims for sustained success.

Arcutis Biotherapeutics reports stellar Q4 performance and raises 2026 guidance

Arcutis Biotherapeutics delivered a strong performance in Q4 2025, with significant revenue growth and positive cash flow, positioning the company for sustained growth in 2026. Despite short-term challenges like seasonal revenue reductions and expense increases, the company's strategic strengths and opportunities bode well for future success. By focusing on market opportunities and maintaining financial discipline, Arcutis Biotherapeutics aims to drive shareholder value and capitalize on the momentum of ZORYVE.